US 11,884,671 B2
Purinone compounds and their use in treating cancer
Maurice Raymond Verschoyle Finlay, Cambridge (GB); Frederick Woolf Goldberg, Cambridge (GB); Martin Richard Howard, Cambridge (GB); and Attilla Kuan Tsuei Ting, Cambridge (GB)
Assigned to AstraZeneca AB, Södertälje (SE); and Cancer Research Technology Limited, London (GB)
Appl. No. 16/973,862
Filed by ASTRAZENECA AB, Södertälje (SE); and CANCER RESEARCH TECHNOLOGY LIMITED, London (GB)
PCT Filed Jun. 14, 2019, PCT No. PCT/EP2019/065686
§ 371(c)(1), (2) Date Dec. 10, 2020,
PCT Pub. No. WO2019/238929, PCT Pub. Date Dec. 19, 2019.
Claims priority of provisional application 62/685,325, filed on Jun. 15, 2018.
Prior Publication US 2021/0171525 A1, Jun. 10, 2021
Int. Cl. C07D 473/32 (2006.01); A61K 9/127 (2006.01); A61K 31/437 (2006.01); A61K 31/502 (2006.01); A61K 31/522 (2006.01); A61K 31/5377 (2006.01); A61K 31/704 (2006.01); A61N 5/10 (2006.01)
CPC C07D 473/32 (2013.01) [A61K 9/127 (2013.01); A61K 31/437 (2013.01); A61K 31/502 (2013.01); A61K 31/522 (2013.01); A61K 31/5377 (2013.01); A61K 31/704 (2013.01); A61N 5/10 (2013.01); C07B 2200/13 (2013.01)] 22 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein:
A1 represents N or CR2A, A2 represents N or CR2B and A3 represents N or CR2C, where no more than one of A1, A2 and A3 represent N;
R1 represents C4-6 cycloalkyl or a 4 to 6 membered heterocycloalkyl containing one heteroatom selected from O, S and N, wherein the C4-6 cycloalkyl or 4 to 6 membered heterocycloalkyl is optionally substituted with one or more groups selected from fluoro, C1-3 alkyl (optionally substituted with a group selected from hydroxyl and C1-2 alkoxy), cyclopropyl, hydroxyl, NH2, dioxo, C(O)C1-2 alkyl, azetidinyl and oxetanyl;
R2A, R2B and R2C each independently represent hydrogen, methyl or methoxy.